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ATTD, February 18-21 2015, Paris 
Sabrina Lyngbye Wendt1,2, Anders Valeur1, Henrik Madsen2, John Bagterp Jørgensen2, Carsten Boye Knudsen1 
1 Zealand Pharma A/S, 2 Technical University of Denmark 
PHARMACOKINETICS MODELING OF GLUCAGON AND A NOVEL GLUCAGON 
ANALOGUE AFTER SUBCUTANEOUS ADMINISTRATION IN DOGS 
Background 
Conclusions 
 
Zealand’s novel glucagon analogue, ZP-GA-1, shows similar PK characteristics (absorption, elimination, volume of distribution) to 
native glucagon. Time to maximum concentration, Tmax, is also similar between native glucagon and ZP-GA-1. However, ZP-GA-1 has 
lower maximum concentration, Cmax,  than native glucagon after same level of dose administration.  
Currently available hypoglycemic glucagon rescue kits are difficult to handle and need reconstitution immediately before use due to the 
instability of native glucagon in solution. A novel Zealand Pharma invented glucagon analogue (ZP-GA-1) with increased stability in liquid 
formulation has potential for application in a ready-to-use rescue pen. Pharmacokinetic (PK) characteristics similar to native glucagon and fast 
on-set of action are critical for success. 
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Variable Mean (±SD) Mean (±SD) Mean (±SD) Mean (±SD) 
Tmax (min) 
Cmax/D (kg/L) 
k01 (min-1) 
k10 (min-1) 
VF/W (L/kg) 
24 (±14) 
0.065 (±0.032) 
0.26 (±0.39) 
0.016 (±0.007) 
12.7 (±3.9) 
30 (±11) 
0.043 (±0.008) 
0.07 (±0.05) 
0.025 (±0.027) 
13.4 (±5.2) 
20 (±5) 
0.096 (±0.015) 
0.12 (±0.05) 
0.018 (±0.004) 
7.4 (±1.5) 
26 (±9) 
0.058 (±0.010) 
0.11 (±0.10) 
0.016 (±0.007) 
11.6 (±4.0) 
Variable Dependency P-value 
Cmax/D (kg/L) Compound 0.04 
Results 
Figure 1: PK profiles after low SC dose. A) Raw observations with best 
fit to population data. B) Semi logarithmic plot with observations and 
best fit to population data. C) Semi logarithmic plot with individual fits. 
Figure 2: PK profiles after high SC dose. A) Raw observations with best 
fit to population data. B) Semi logarithmic plot with observations and 
best fit to population data. C) Semi logarithmic plot with individual fits. 
Methods 
Five dogs were included in a randomized cross-over study. At four 
dosing occasions each dog received a subcutaneous (SC) bolus 
injection of 20 or 120 nmol/kg (D) native glucagon or ZP-GA-1. Blood 
samples were collected at 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 110, 140, 
and 180 minutes after dose administration. Sample concentration (y) of 
glucagon were analyzed using the MSD immuno assay. Plasma 
concentration (y) of ZP-GA-1 were analyzed using LC-MS/MS.  
A one compartment model with extravascular bolus administration was 
fitted to each individual dataset and each population by minimizing the  
y-1-weighted residual sum of squares using a BFGS quasi-Newton 
optimization algorithm in R version 3.1.0 “Spring Dance”. Tmax, a 
surrogate marker of on-set of action, and Cmax was obtained from the fit. 
Table 1: Population means and standard deviations (SD) of model parameters (k01, k10, VF/W) and model 
fit characteristics (Tmax, Cmax/D).  
Table 2: Significant variable and its dependency 
according to a two-way (Dose*Compound) within 
subjects ANOVA analysis. P-values of remaining 
model parameters and model fit characteristics were 
not significant. 
𝑢 𝑡 = 𝛿(𝑡) ∙ 𝐷 
